
In many zzso nations, obesity is now considered an epidemic, resulting in accelerated morbidity and zzso zzso is associated with an increased risk of coronary artery disease as well as the zzso syndrome zzso abdominal zzso increased zzso blood zzso levels, zzso and hypertension, which are all recognized cardiovascular risk zzso zzso exercise, and lifestyle changes constitute important recommendations for zzso Unfortunately, although effective in some individuals, these recommendations have proven to be ineffective in adequately addressing the zzso enlarging scope of this public health zzso Drug treatment is often indicated but is somewhat limited by the minimal number of well tolerated drugs that have proven to have long-term efficacy in maintaining zzso zzso For example, zzso may result in modest zzso loss through suppression of zzso but potential cardiovascular adverse effects exist and the efficacy is mainly zzso zzso an inhibitor of zzso and zzso zzso zzso may increase zzso and result in modest zzso zzso However, cardiovascular adverse effects may occur in susceptible zzso Nonetheless, zzso is one of the few drugs that has been approved by the US Food and Drug Administration zzso for zzso zzso zzso a zzso zzso is also approved by the zzso for zzso loss but may have zzso gastrointestinal adverse effects, especially among patients who do not adhere to the recommended low-fat zzso zzso studies continue to evaluate other drug treatments that may result in zzso reduction through a number of different zzso It is anticipated that the development of effective and well tolerated zzso drugs will elevate the zzso treatment of obesity to the status of other cardiovascular risk factors and zzso zzso This may be especially important given that zzso hypertension and type 2 diabetes zzso are often secondary to, or exacerbated by, zzso 

